N,N-bis-2-mercaptoethyl isophthalamide, or a pharmaceutically acceptable salt or derivative thereof, for use in the treatment of a neurodegenerative disorder, preferably selected from Alzheimers disease, Parkinsons disease, Huntingtons disease or amyotrophic lateral sclerosis. Preferably the pharmaceutically acceptable derivatives of N,N-bis-2-mercaptoethyl isophthalamide include glutathione, cysteine, alphadihydrolipoic acid, cystamine, thiolphosphate, 5-thioladenosine, L-homocysteine, co-enzyme A, 2-mercaptoethanol, dithiothreitol, iodoacetate, bromoacetate, fluoroacetate or chloroacetate derivatives.
